Literature DB >> 2469694

Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy.

S A Schiogolev1, E J Goetzl, W J Urba, D L Longo.   

Abstract

Administration of intravenous interleukin-2 (IL-2), followed by intraperitoneal IL-2 and autologous lymphokine-activated killer (LAK) cells to six patients with colonic, ovarian, or endometrial carcinoma restricted to peritoneal spread increased significantly the ascitic fluid concentrations of the neuropeptides substance P (SP) and calcitonin-gene related peptide (CGRP). After intravenous IL-2 alone, the level of SP rose 10- to 140-fold, without a change in that of CGRP. Intraperitoneal IL-2 and LAK cells led to elevations in the concentrations of SP and CGRP to respective maximal means of 319 and 175 pM after 8 hr, which were maintained for 24-48 hr without alterations in the levels of vasoactive intestinal peptide or somatostatin. SP and CGRP from peritoneal fluid were chromatographically indistinguishable from synthetic neuropeptides. The increases in concentrations of SP and CGRP after IL-2 and LAK-cell therapy are the first demonstration of a neural response to a human cellular immunological reaction. The time course and magnitude of the neuropeptide response suggest a role in the vascular side effects of this form of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469694     DOI: 10.1007/bf00916945

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  9 in total

1.  Potent vasodilator activity of calcitonin gene-related peptide in human skin.

Authors:  S D Brain; J R Tippins; H R Morris; I MacIntyre; T J Williams
Journal:  J Invest Dermatol       Date:  1986-10       Impact factor: 8.551

2.  Selective localization of vasoactive intestinal peptide and substance P in human eosinophils.

Authors:  J Aliakbari; S P Sreedharan; C W Turck; E J Goetzl
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

3.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

4.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.

Authors:  R Lafreniere; S A Rosenberg
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  Intraperitoneal administration of interleukin-2 in patients with cancer.

Authors:  M T Lotze; M C Custer; S A Rosenberg
Journal:  Arch Surg       Date:  1986-12

6.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

Authors:  M T Lotze; A E Chang; C A Seipp; C Simpson; J T Vetto; S A Rosenberg
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

7.  Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.

Authors:  M Z Papa; J J Mulé; S A Rosenberg
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

8.  Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen.

Authors:  K B Walker; M H Serwonska; F H Valone; W S Harkonen; O L Frick; K H Scriven; W D Ratnoff; J G Browning; D G Payan; E J Goetzl
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

9.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.